清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

帕妥珠单抗 曲妥珠单抗 多西紫杉醇 医学 内科学 乳腺癌 肿瘤科 人口 化疗 癌症 临床终点 临床试验 环境卫生
作者
Luca Gianni,Tadeusz Pieńkowski,Young‐Hyuck Im,Laslo Roman,Ling‐Ming Tseng,Mei-Ching Liu,Ana M. Lluch,Elżbieta Starosławska,Juan de la Haba-Rodríguez,Seock‐Ah Im,José Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Владимир Федорович Семиглазов,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham A. Ross,Pinuccia Valagussa
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:13 (1): 25-32 被引量:2393
标识
DOI:10.1016/s1470-2045(11)70336-9
摘要

Background Studies with pertuzumab, a novel anti-HER2 antibody, show improved efficacy when combined with the established HER2-directed antibody trastuzumab in breast cancer therapy. We investigated the combination of pertuzumab or trastuzumab, or both, with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting. Methods In this multicentre, open-label, phase 2 study, treatment-naive women with HER2-positive breast cancer were randomly assigned (1:1:1:1) centrally and stratified by operable, locally advanced, and inflammatory breast cancer, and by hormone receptor expression to receive four neoadjuvant cycles of: trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus docetaxel (75 mg/m2, escalating, if tolerated, to 100 mg/m2 every 3 weeks; group A) or pertuzumab (loading dose 840 mg, followed by 420 mg every 3 weeks) and trastuzumab plus docetaxel (group B) or pertuzumab and trastuzumab (group C) or pertuzumab plus docetaxel (group D). The primary endpoint, examined in the intention-to-treat population, was pathological complete response in the breast. Neither patients nor investigators were masked to treatment. This study is registered with ClinicalTrials.gov, number NCT00545688. Findings Of 417 eligible patients, 107 were randomly assigned to group A, 107 to group B, 107 to group C, and 96 to group D. Patients given pertuzumab and trastuzumab plus docetaxel (group B) had a significantly improved pathological complete response rate (49 of 107 patients; 45·8% [95% CI 36·1–55·7]) compared with those given trastuzumab plus docetaxel (group A; 31 of 107; 29·0% [20·6–38·5]; p=0·0141). 23 of 96 (24·0% [15·8–33·7]) women given pertuzumab plus docetaxel (group D) had a pathological complete response, as did 18 of 107 (16·8% [10·3–25·3]) given pertuzumab and trastuzumab (group C). The most common adverse events of grade 3 or higher were neutropenia (61 of 107 women in group A, 48 of 107 in group B, one of 108 in group C, and 52 of 94 in group D), febrile neutropenia (eight, nine, none, and seven, respectively), and leucopenia (13, five, none, and seven, respectively). The number of serious adverse events was similar in groups A, B, and D (15–20 serious adverse events per group in 10–17% of patients) but lower in group C (four serious adverse events in 4% of patients). Interpretation Patients given pertuzumab and trastuzumab plus docetaxel (group B) had a significantly improved pathological complete response rate compared with those given trastuzumab plus docetaxel, without substantial differences in tolerability. Pertuzumab and trastuzumab without chemotherapy eradicated tumours in a proportion of women and showed a favourable safety profile. These findings justify further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer. Funding F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
彭于晏的应助被xuxu213采纳,获得10
6秒前
369ninja发布了新的文献求助10
11秒前
xuxu213完成签到,获得积分20
16秒前
大个的应助被科研通管家采纳,获得10
17秒前
19秒前
Teio完成签到 ,获得积分10
22秒前
xuxu213发布了新的文献求助10
25秒前
搞怪的萧完成签到,获得积分10
26秒前
着急的冷珍完成签到,获得积分10
29秒前
QiWei完成签到 ,获得积分10
46秒前
从容的绿蝶完成签到,获得积分10
50秒前
博士搏斗完成签到 ,获得积分10
50秒前
噼里啪啦完成签到,获得积分10
59秒前
可爱沛蓝完成签到 ,获得积分10
1分钟前
1分钟前
xuxu213发布了新的文献求助10
1分钟前
酷酷的海莲完成签到,获得积分10
1分钟前
称心怜菡完成签到,获得积分10
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
cat发布了新的文献求助10
1分钟前
廖道罡完成签到,获得积分10
1分钟前
Hello的应助被gyc采纳,获得10
1分钟前
Gilgardea发布了新的文献求助10
1分钟前
1分钟前
听话的尔竹完成签到,获得积分10
1分钟前
gyc完成签到,获得积分10
1分钟前
独特问梅完成签到,获得积分10
1分钟前
gyc发布了新的文献求助10
1分钟前
大明完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被cat采纳,获得10
1分钟前
Zhangym完成签到 ,获得积分10
1分钟前
魔幻雪兰完成签到,获得积分10
1分钟前
智者雨人完成签到 ,获得积分10
2分钟前
沉默怡完成签到,获得积分10
2分钟前
FashionBoy的应助被朱洪帆采纳,获得10
2分钟前
坚强夜梦完成签到,获得积分10
2分钟前
852的应助被朱洪帆采纳,获得10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166414
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750507
捐赠科研通 7757221
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553489
邀请新用户注册赠送积分活动 2473845